More payers are trying to rein in the use of antipsychotics in patients WITHOUT psychotic disorders

December 2013

More payers are trying to rein in the use of antipsychotics in patients WITHOUT psychotic disorders.

Almost $6 BILLION a year is spent on Abilify alone.

Now the Choosing Wisely report and others are pointing out when the risks of antipsychotics are likely to outweigh their benefit.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Opioids BIG changes with hydrocodone (Vicodin, etc)
Obesity Weight Loss More obese patients will get bariatric surgery and need help with their meds afterward
Vaccines proper administration of vaccines
Med Adherence more reasons to improve med adherence
Acute Pain more focus on the management of ACUTE low back pain to counter the increasing use of opioids, benzodiazepines, and imaging
Pneumonia more emphasis on prevention and treatment of community-acquired pneumonia
Antidepressants two new antidepressants, Brintellix (brin-TEL-ix, vortioxetine) and Fetzima (fet-ZEE-muh, levomilnacipran)
Antipsychotics More payers are trying to rein in the use of antipsychotics in patients WITHOUT psychotic disorders
HIV AIDS New simplified guidelines for HIV prophylaxis after a needlestick
Oral Health Patients are asking for help choosing tooth whiteners
Substance Use Disorder "Molly," the party drug
Dyslipidemia more lipid drugs get indications based on HARD clinical outcomes